{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:15:53Z","timestamp":1788279353759,"version":"build-2803163510"},"reference-count":41,"publisher":"The Journal of Rheumatology","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2026,5,11]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>The increasing use of targeted immunomodulatory therapies for psoriasis and atopic dermatitis has transformed disease management. However, paradoxical and treatment-induced cutaneous adverse and musculoskeletal events are being increasingly recognized that often mimic or deviate from the primary disease phenotype. This review summarizes current evidence on the clinical manifestations, underlying pathophysiological mechanisms, and therapeutic strategies for biologic-induced cutaneous and articular reactions in immune-mediated dermatoses. We highlight reactions associated with tumor necrosis factor, interleukin (IL)-17, IL-23, and IL-4\/IL-13 inhibitors, discussing diagnostic challenges and immunologic shifts underlying these phenomena. Recognition of these distinct entities is critical to avoid misinterpretation as treatment failure and to optimize patient care through tailored management strategies and shared decision making.<\/jats:p>","DOI":"10.3899\/jrheum.2026-0480","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:20:20Z","timestamp":1781526020000},"page":"37-40","source":"Crossref","is-referenced-by-count":0,"title":["Targeted Therapy, Untargeted Rash: Insights From a GRAPPA Workshop on Immune Shifts in Psoriatic Disease"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-3115","authenticated-orcid":false,"given":"Leandro Linhares","family":"Leite","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-8924","authenticated-orcid":false,"given":"Andr\u00e9 L.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3484-7977","authenticated-orcid":false,"given":"Jeffrey","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"2026090108201668000_53.Suppl_2.37.1","doi-asserted-by":"publisher","DOI":"10.1177\/2475530318810851"},{"key":"2026090108201668000_53.Suppl_2.37.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4"},{"key":"2026090108201668000_53.Suppl_2.37.3","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.4","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jaad.2018.12.018","article-title":"TNF-alpha inhibitor-induced psoriasis: a decade of experience at the Cleveland Clinic","volume":"83","author":"Mazloom","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.5","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.36849\/JDD.7645","article-title":"A case series of TNF inhibitor-induced psoriasis successfully treated with upadacitinib","volume":"23","author":"Woodbury","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.6","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s13555-016-0151-4","article-title":"Psoriasiform eruption and worsening of pustulosis palmoplantaris after treatment with two anti-TNF-alpha inhibitors, followed by successful treatment with ustekinumab","volume":"6","author":"Bogaards","year":"2016","journal-title":"Dermatol Ther"},{"key":"2026090108201668000_53.Suppl_2.37.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09329.x"},{"key":"2026090108201668000_53.Suppl_2.37.8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/14712598.2020.1727439","article-title":"Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature","volume":"20","author":"Caldarola","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2026090108201668000_53.Suppl_2.37.9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamadermatol.2023.4846","article-title":"Risk of paradoxical eczema in patients receiving biologics for psoriasis","volume":"160","author":"Al-Janabi","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/jamadermatol.2019.1268","article-title":"Morphologic switch from psoriasiform to eczematous dermatitis after anti-IL-17 therapy: a case series","volume":"155","author":"Lai","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54559-6"},{"key":"2026090108201668000_53.Suppl_2.37.12","doi-asserted-by":"publisher","DOI":"10.1111\/all.15921"},{"key":"2026090108201668000_53.Suppl_2.37.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2205982"},{"key":"2026090108201668000_53.Suppl_2.37.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"2026090108201668000_53.Suppl_2.37.15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Experimental Allergy"},{"key":"2026090108201668000_53.Suppl_2.37.16","doi-asserted-by":"publisher","DOI":"10.1159\/000530608"},{"key":"2026090108201668000_53.Suppl_2.37.17","doi-asserted-by":"crossref","first-page":"e9590","DOI":"10.1002\/ccr3.9590","article-title":"Dupilumab-induced erythrodermic psoriasiform dermatitis in chronic actinic dermatitis: case report and innovative treatment approach","volume":"12","author":"Khodeir","year":"2024","journal-title":"Clin Case Rep"},{"key":"2026090108201668000_53.Suppl_2.37.18","doi-asserted-by":"crossref","first-page":"2333016","DOI":"10.1080\/09546634.2024.2333016","article-title":"A pediatric case of dupilumab-induced pustular psoriasis","volume":"35","author":"Dang","year":"2024","journal-title":"J Dermatol Treat"},{"key":"2026090108201668000_53.Suppl_2.37.19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/pde.15497","article-title":"Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients","volume":"41","author":"Lockard","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.20","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1111\/pde.14820","article-title":"Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children","volume":"38","author":"Parker","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.21","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1111\/jdv.17050","article-title":"De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort","volume":"35","author":"Jaulent","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026090108201668000_53.Suppl_2.37.22","doi-asserted-by":"crossref","first-page":"e13142","DOI":"10.1111\/dth.13142","article-title":"Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series","volume":"32","author":"Napolitano","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026090108201668000_53.Suppl_2.37.23","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.3390\/jcm12196291","article-title":"\u201cDe novo\u201d psoriasis and relapse of psoriasis induced by dupilumab: three new cases and review of the literature","volume":"12","author":"Trave","year":"2023","journal-title":"J Clin Med"},{"key":"2026090108201668000_53.Suppl_2.37.24","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1578"},{"key":"2026090108201668000_53.Suppl_2.37.25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ced\/llad390","article-title":"Dupilumab-associated inflammatory arthritis: a literature review","volume":"49","author":"Napolitano","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/bjd.18031","article-title":"Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series","volume":"181","author":"Willsmore","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1363"},{"key":"2026090108201668000_53.Suppl_2.37.28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40257-023-00804-5","article-title":"Dupilumab-associated arthritis: a dermatology-rheumatology perspective","volume":"24","author":"Woodbury","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2023.08.025","article-title":"Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: a US nationwide cohort study","volume":"90","author":"Schneeweiss","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.30","doi-asserted-by":"crossref","unstructured":"Yang K , Mircescu A , Okusanya D , Understanding the atopic dermatitis-psoriasis phenotypic switch through a mechanistic epidemiology approach. medRxiv 2025 May 26 [Preprint. Accessed May 12, 2026.] Available from: doi.org\/10.1101\/2025.05.25.25328309","DOI":"10.1101\/2025.05.25.25328309"},{"key":"2026090108201668000_53.Suppl_2.37.31","doi-asserted-by":"crossref","first-page":"e1432","DOI":"10.1111\/jdv.19351","article-title":"Successful treatment with tralokinumab in patients with atopic dermatitis and dupilumab-induced psoriasis","volume":"37","author":"Quattrini","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026090108201668000_53.Suppl_2.37.32","first-page":"16","article-title":"Tralokinumab as a therapeutic alternative for dupilumab-associated arthralgia in atopic dermatitis: a multi-center case series","volume":"18","author":"Greenberg","year":"2025","journal-title":"J Clin Aesthet Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.33","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/art.42558","article-title":"Characterization of a musculoskeletal syndrome of enthesitis and arthritis in patients with atopic dermatitis treated with dupilumab, an Interleukin-4\/13 inhibitor","volume":"75","author":"Hughes","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2026090108201668000_53.Suppl_2.37.34","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/rheumatology\/keaa568","article-title":"Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy","volume":"60","author":"Bridgewood","year":"2021","journal-title":"Rheumatology"},{"key":"2026090108201668000_53.Suppl_2.37.35","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17-type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.36","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1007\/s13555-023-01000-3","article-title":"Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis","volume":"13","author":"Silverberg","year":"2023","journal-title":"Dermatol Ther"},{"key":"2026090108201668000_53.Suppl_2.37.37","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309106176"},{"key":"2026090108201668000_53.Suppl_2.37.38","first-page":"465","article-title":"A systematic review of drug-induced subacute cutaneous lupus erythematosus","volume":"164","author":"Lowe","year":"2011","journal-title":"Br J Dermatol"},{"key":"2026090108201668000_53.Suppl_2.37.39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D371G1B76B","article-title":"Lamotrigine induced subacute cutaneous lupus erythematous","volume":"18","author":"Cabanillas","year":"2012","journal-title":"Dermatol Online J"},{"key":"2026090108201668000_53.Suppl_2.37.40","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-008-0890-x"},{"key":"2026090108201668000_53.Suppl_2.37.41","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3390\/jcm12030987","article-title":"Current knowledge of the molecular pathogenesis of cutaneous lupus erythematosus","volume":"12","author":"Miyagawa","year":"2023","journal-title":"J Clin Med"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2026-0480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:20:28Z","timestamp":1788276028000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2026-0480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":41,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.3899\/jrheum.2026-0480"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2026-0480","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]}}}